Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial

Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial

Abstract Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins. We implemented a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavi...

Full description

Bibliographic Details
Main Authors: Fabrice Bonnet, Adama Doumbia, Vanessa Machault, Frederic Nogbou Ello, Pantxika Bellecave, Corine Bernice Akpovo, Baba Toumany Sidibe, Laura Fernandez, Antoine Kouamé, Edgard Adjogoua, Mireille Dosso, Serge Niangoran, Valérie Journot, Serge Paul Eholié
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
SARS-CoV-2
Atorvastatin
Telmisartan
Randomized controlled trial
Online Access:https://doi.org/10.1038/s41598-024-72449-1

Internet

https://doi.org/10.1038/s41598-024-72449-1

Similar Items